Related Experiment Video
Updated: May 31, 2026

Isolation and Cultivation of Neural Progenitors Followed by Chromatin-Immunoprecipitation of Histone 3 Lysine 79 Dimethylation Mark
Published on: January 26, 2018
SPARC Drives Tubulointerstitial Fibrosis through Regulating the CBP-DOT1L Pathway
Huimin Jiang1, Qing Yang1, Kuo Wang1
1Department of Nephrology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing, P.R. China.
SPARC protein drives kidney fibrosis by stabilizing DOT1L, a key epigenetic regulator. Targeting the SPARC-CBP-DOT1L pathway offers a novel therapeutic strategy for chronic kidney disease (CKD).
Area of Science:
- Nephrology
- Molecular Biology
- Epigenetics
Background:
- Renal tubulointerstitial fibrosis (TIF) is a major driver of chronic kidney disease (CKD) progression.
- Current anti-fibrotic therapies for CKD are limited, necessitating new therapeutic targets.
Purpose of the Study:
- To identify key mediators of TIF and explore potential therapeutic targets for CKD.
Main Methods:
- Correlation analysis of SPARC expression in human CKD biopsies and murine models (UUO, IRI).
- Genetic ablation of Sparc in murine models to assess its role in renal fibrosis.
- Investigation of the SPARC-CBP-DOT1L signaling axis and its epigenetic modifications (H3K79me2).
Main Results:
- SPARC expression correlates strongly with fibrosis severity in human and murine kidneys.
- Genetic deletion of Sparc significantly reduces renal fibrosis in UUO and IRI models.
- SPARC stabilizes DOT1L via the CBP-MEK-ERK pathway, enhancing H3K79me2 and promoting PTECs fibrosis.
Conclusions:
- SPARC is a critical mediator of renal tubulointerstitial fibrosis (TIF) in chronic kidney disease (CKD).
- The SPARC-CBP-DOT1L signaling cascade represents a novel epigenetic pathway driving renal fibrosis.
- Targeting the SPARC-CBP-DOT1L axis holds promise for developing new anti-fibrotic therapies for CKD.
Related Concept Videos
The JAK-STAT Signaling Pathway
Abnormal Proliferation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...